MedTrace Logo

Cardiometabolic Effects of Pecans as a Snack

NCT05071807 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2025-02-25

Study results available
· View outcomes & findings →

Summary

A randomized, 2-arm, parallel trial will be conducted to examine the effect of pecans on markers of peripheral vascular health, lipids and lipoproteins, blood pressure, and glycemic control.

Conditions

Interventions

DRUG

Pecans

Participants will receive 2 oz of pecans daily to replace a typical snack and continue consuming their usual diet for 12 weeks.

OTHER

Usual Care

Participants will receive grocery vouchers and continue consuming their usual diet for 12 weeks.

Sponsors & Collaborators

  • American Pecan Council

    collaborator OTHER

  • Penn State University

    lead OTHER

Principal Investigators

  • Kristina Petersen, PhD · Penn State University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-15
Primary Completion
2024-03-01
Completion
2024-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05071807 on ClinicalTrials.gov